PMID- 38236367
OWN - NLM
STAT- MEDLINE
DCOM- 20240119
LR  - 20240202
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
VI  - 51
IP  - 1
DP  - 2024 Jan 18
TI  - In vitro and in vivo anti-tumor effect of Trichobakin fused with urokinase-type 
      plasminogen activator ATF-TBK.
PG  - 130
LID - 10.1007/s11033-023-09036-6 [doi]
AB  - BACKGROUND: Trichobakin (TBK), a member of type I ribosome-inactivating proteins 
      (RIPs), was first successfully cloned from Trichosanthes sp Bac Kan 8-98 in 
      Vietnam. Previous study has shown that TBK acts as a potential protein synthesis 
      inhibitor; however, the inhibition efficiency and specificity of TBK on cancer 
      cells remain to be fully elucidated. METHODS AND RESULTS: In this work, we 
      employed TBK and TBK conjugated with a part of the amino-terminal fragment (ATF) 
      of the urokinase-type plasminogen activator (uPA), which contains the Omega-loop that 
      primarily interacts with urokinase-type plasminogen activator receptor, and can 
      be a powerful carrier in the drug delivery to cancer cells. Four different human 
      tumor cell lines and BALB/c mice bearing Lewis lung carcinoma cells (LLC) were 
      used to evaluate the role of TBK and ATF-TBK in the inhibition of tumor growth. 
      Here we showed that the obtained ligand fused RIP (ATF-TBK) reduced the growth of 
      four human cancer cell lines in vitro in the uPA receptor level-dependent manner, 
      including the breast adenocarcinoma MDA-MB 231 cells and MCF7 cells, the prostate 
      carcinoma LNCaP cells and the hepatocellular carcinoma HepG2 cells. Furthermore, 
      the conjugate showed anti-tumor activity and prolonged the survival time of 
      tumor-bearing mice. The ATF-TBK also did not cause the death of mice with doses 
      up to 48 mg/kg, and they were not significantly distinct on parameters of 
      hematology and serum biochemistry between the control and experiment groups. 
      CONCLUSIONS: In conclusion, ATF-TBK reduced the growth of four different human 
      tumor cell lines and inhibited lung tumor growth in a mouse model with little 
      side effects. Hence, the ATF-TBK may be a target to consider as an anti-cancer 
      agent for clinical trials.
CI  - (c) 2024. The Author(s), under exclusive licence to Springer Nature B.V.
FAU - Pham, Dan Duc
AU  - Pham DD
AD  - Institute of Biotechnology (IBT), Vietnam Academy of Science and Technology 
      (VAST), 18, Hoang Quoc Viet Road, Cau Giay, Hanoi, Vietnam.
FAU - Pham, Thi Hue
AU  - Pham TH
AD  - Institute of Biotechnology (IBT), Vietnam Academy of Science and Technology 
      (VAST), 18, Hoang Quoc Viet Road, Cau Giay, Hanoi, Vietnam.
FAU - Bui, Thi Huyen
AU  - Bui TH
AD  - Institute of Biotechnology (IBT), Vietnam Academy of Science and Technology 
      (VAST), 18, Hoang Quoc Viet Road, Cau Giay, Hanoi, Vietnam.
FAU - Britikova, Elena V
AU  - Britikova EV
AD  - Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, 
      220141, Minsk, Belarus.
FAU - Britikov, Vladimir V
AU  - Britikov VV
AD  - Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, 
      220141, Minsk, Belarus.
FAU - Bocharov, Eduard V
AU  - Bocharov EV
AD  - Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of 
      Sciences, Moscow, Russia, 117997.
FAU - Usanov, Sergey A
AU  - Usanov SA
AD  - Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, 
      220141, Minsk, Belarus.
FAU - Phan, Van Chi
AU  - Phan VC
AD  - Institute of Biotechnology (IBT), Vietnam Academy of Science and Technology 
      (VAST), 18, Hoang Quoc Viet Road, Cau Giay, Hanoi, Vietnam.
FAU - Le, Thi Bich Thao
AU  - Le TBT
AD  - Institute of Biotechnology (IBT), Vietnam Academy of Science and Technology 
      (VAST), 18, Hoang Quoc Viet Road, Cau Giay, Hanoi, Vietnam. lethao@ibt.ac.vn.
AD  - Graduate University of Science and Technology, Vietnam Academy of Science and 
      Technology, Hanoi, Vietnam. lethao@ibt.ac.vn.
LA  - eng
GR  - QTRU05.01/21-23/The Vietnam Academy of Science and Technology/
GR  - VINIF.2023.STS.28/The Postdoctoral Scholarship Programme of Vingroup Innovation 
      Foundation (VINIF)/
GR  - capital HA, Cyrillic20capital IE, Cyrilliccapital A, Cyrillic-027/BRFBR/
GR  - 20-54-81015/RFBR/
PT  - Journal Article
DEP - 20240118
PL  - Netherlands
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
SB  - IM
MH  - Humans
MH  - Male
MH  - Animals
MH  - Mice
MH  - Urokinase-Type Plasminogen Activator
MH  - Drug Delivery Systems
MH  - *Prostatic Neoplasms
MH  - *Lung Neoplasms
MH  - Cell Line, Tumor
OTO - NOTNLM
OT  - ATF-TBK
OT  - Cytotoxic activity
OT  - Ribosome inactivating protein (RIP)
OT  - Trichobakin (TBK)
OT  - Urokinase plasminogen activator (uPA)
EDAT- 2024/01/18 12:42
MHDA- 2024/01/19 06:42
CRDT- 2024/01/18 11:19
PHST- 2023/08/22 00:00 [received]
PHST- 2023/11/28 00:00 [accepted]
PHST- 2024/01/19 06:42 [medline]
PHST- 2024/01/18 12:42 [pubmed]
PHST- 2024/01/18 11:19 [entrez]
AID - 10.1007/s11033-023-09036-6 [pii]
AID - 10.1007/s11033-023-09036-6 [doi]
PST - epublish
SO  - Mol Biol Rep. 2024 Jan 18;51(1):130. doi: 10.1007/s11033-023-09036-6.